Does GLP-1 Cause Cancer?

The short answer

No GLP-1 medication has been shown to cause cancer in humans at a population level, but the question is not closed. The FDA label for every weekly GLP-1 (Wegovy, Ozempic, Zepbound, Mounjaro) carries a boxed warning about thyroid C-cell tumors based on rodent studies. A separate pancreatic-cancer signal has appeared in some retrospective databases. The largest meta-analysis to date — about 46,000 people across 37 trials — did not find an increased risk of cancer overall.

What the research says

The boxed warning is the loudest piece. In two-year rodent studies, semaglutide and other long-acting GLP-1 receptor agonists caused medullary thyroid carcinoma in rats at clinically relevant exposures. The mechanism appears to involve sustained GLP-1 receptor activation on thyroid C cells, which rats have far more of than humans do. Whether this translates to humans is, in the FDA's own words, unknown. Because of this uncertainty, the drugs are contraindicated in anyone with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN-2).

The pancreatic-cancer question is older and harder to pin down. Early case-series data from the 2010s raised concern that GLP-1 agonists might increase rates of acute pancreatitis and, downstream, pancreatic cancer. Subsequent meta-analyses have been mostly reassuring. A 2019 pooled analysis did not find a significantly elevated risk of acute pancreatitis. A 2023 systematic review of 46,719 individuals across major trials reported that semaglutide use over 18 months was not associated with increased risk of any cancer. Pancreatitis remains on every GLP-1 label as a warning, but the cancer signal has not solidified.

There are also signals that point the other direction. GLP-1 medications produce substantial sustained weight loss, and obesity is itself a documented risk factor for at least 13 cancers (endometrial, esophageal, kidney, postmenopausal breast, colorectal, and others). The SELECT cardiovascular outcomes trial of semaglutide showed broad metabolic improvements that, modeled out over decades, would plausibly reduce many of these obesity-driven cancers. That hypothesis has not been proven in long-term cancer outcomes data — those studies don't exist yet — but it is the other half of the risk-benefit conversation.

Real-world post-marketing surveillance now spans hundreds of millions of patient-doses across the GLP-1 class. No specific human cancer has reached the threshold for a class-wide label revision beyond the thyroid C-cell language already present. New signals are studied as they appear.

What this means for you

If you have a personal or family history of medullary thyroid carcinoma or MEN-2, GLP-1 medications are off the table. That is a hard contraindication, not a discussion point. If you have a thyroid nodule of unknown character, your provider may want imaging or a calcitonin level before starting therapy, depending on your risk profile.

If you have a history of pancreatitis or a first-degree relative with pancreatic cancer, that is a conversation, not a contraindication. Some prescribers will start therapy with closer monitoring; others will steer you to an alternative. Either approach is defensible.

For most other adults considering a GLP-1, the cancer question lands like this: the documented risks are specific and narrow (thyroid C-cell tumors in rodents, pancreatitis signal under monitoring), and the documented benefits — weight loss, cardiovascular event reduction, glycemic control — are broad and well-quantified. Reasonable people facing meaningful obesity-related health risk often decide the trade favors treatment, with their provider's input.

Common questions

Keep exploring

Browse all GLP-1 guides.